WASHINGTON (Legal Newsline) — District of Columbia Attorney General Karl A. Racine announced July 18 he has joined four other states in a lawsuit against a group of generic drug manufacturers over allegations of conspiring to fix drug prices, thwart competition and engage in illegal and anti-competitive trade practices.
The six drug companies named in the lawsuit, filed in the U.S. District Court for the District of Connecticut, are Heritage Pharmaceuticals Inc., Aurobindo Pharma USA Inc., Citron Pharma LLC, Mayne Pharma (USA) Inc., Mylan Pharmaceuticals Inc., and Teva Pharmaceuticals USA Inc.
According to allegations, these companies conducted an anti-competitive scheme involving two drugs, doxycycline hyclate delayed release, an antibiotic, and glyburide, an oral diabetes medication.
“District residents rely on the availability of reasonably priced generic drugs to make the medications they need more affordable," Racine said. "We will not tolerate drug companies manipulating markets and increasing their profits at consumers’ expense. “It is unacceptable for companies to flout federal and state laws that are designed to protect consumers.”
The attorney general of Connecticut is leading the coalition in the case.